Using Glialia to treat Persistent Perceptual Postural Dizziness
Official title: Use of the Glialia Supplement in the Treatment of Persistent Perceptual Postural Imbalance: A Triple-Blind, Randomized, Placebo-Controlled Pilot Clinical Trial
Run by LIFE - Research and Care Institute - Santa Lucia IRCCS · NCT06741358 · Data updated 2026-11-12
This study is testing if a supplement called Glialia can help reduce brain inflammation in people with Persistent Perceptual Postural Dizziness compared to those who receive a placebo.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | LIFE - Research and Care Institute - Santa Lucia IRCCS Academic / other |
| Locations | 1 site (Rome, RM) |
| Status | Recruiting |
| Started | December 21, 2024 |
| Main results expected | October 10, 2025 |
| Study ends | May 10, 2027 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT06741358 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 to 65 diagnosed with Persistent Perceptual Postural Dizziness, regardless of previous COVID-19 infection.
✕Probably not a fit
Patients with concurrent neurological or otological disorders, or those who are pregnant, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study involves 30 participants, including 20 patients diagnosed with Persistent Perceptual Postural Dizziness (PPPD) and 10 control participants who have recovered from COVID-19. Participants will be randomly assigned to receive either the Glialia supplement or a placebo, with the aim of comparing neuroinflammation levels between the groups. The study will be conducted in a triple-blind manner to ensure unbiased results, and it seeks to determine if Glialia can significantly reduce neuroinflammation in PPPD patients compared to the placebo group. The outcomes will help assess the influence of previous COVID-19 infection on neuroinflammation levels.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients suffering from Persistent Perceptual Postural Dizziness.
How similar studies have gone: While this approach is novel in the context of PPPD, similar studies targeting neuroinflammation have shown promise in other conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria for all groups: -Age between 18 and 65 years. Inclusion criteria for the PPPD-glialia group: * Diagnosis of PPPD; * Recovery from COVID-19 infection or absence of previous infection. Inclusion criteria for the PPPD-placebo group: * Diagnosis of PPPD; * Recovery from COVID-19 infection or absence of previous infection (matched to the PPPD-glialia group). Exclusion criteria for all PPPD-group: * Presence of concurrent neurological and otological disorders other than PPPD; * Pregnant women. Inclusion criteria for the control group: -Previous COVID-19 infection (matched for timing to the PPPD-glialia group). Exclusion criteria for the control group: * Presence of neurological and otological disorders; * Pregnant women.
Where it's running
-
Fondazione Santa Lucia IRCCS
Rome, Rm, Italy Recruiting
Study contacts
- Principal investigator: Iole Indovina, PhD — Department of Systems Medicine, University of Rome Tor Vergata Rome, Italy ; Centre of Space Bio-medicine, University of Rome Tor Vergata Rome, Italy ; Laboratory of Neuromotor Physiology, IRCCS Santa Lucia Foundation Rome, Italy.
- Study coordinator: Iole Indovina, PhD
- Email: i.indovina@hsantalucia.it
- Phone: 0039 0651501476
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Virtual Reality and Biofeedback for Adolescents with Chronic Dizziness
This study tests a virtual reality and biofeedback approach to help adolescents with chronic dizziness from PPPD or vestibular migraine see if it can reduce symptoms and improve daily function.
-
Manual Therapy Before Neuromotor Rehab in Children with Cerebral Palsy
In this pilot study, researchers test whether 30 minutes of lower-limb manual therapy before functional neuromotor therapy helps improve gait and motor performance in children with spastic cerebral palsy.
-
Timed cerebellar stimulation with immersive virtual reality to boost social prediction
This trial will try personalized cerebellar HD-tACS together with immersive virtual reality to improve social prediction in adolescents and young adults with congenital cerebellar malformations and in adults with degenerative cerebellar atrophy.
-
Gentle Touch therapy for arm lymphedema after breast cancer surgery
We will test whether adding Gentle Touch lymphatic drainage to usual rehabilitation reduces arm swelling in women aged 30–75 with breast cancer–related lymphedema.
-
Personalized non-invasive magnetic and electrical stimulation of memory networks in mild Alzheimer's
This study will try a personalized combination of magnetic (iTBS) and electrical (tACS) non-invasive brain stimulation to improve memory and brain connectivity in people with mild Alzheimer's disease.
-
EMG-controlled virtual hand with cerebellar magnetic stimulation to improve arm recovery after stroke
This program will test whether an EMG-controlled virtual reality hand combined with brief cerebellar magnetic stimulation helps adults (18–79) with mild-to-moderate upper-limb weakness after a first ischemic stroke regain reaching ability and arm function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.